Trials / Completed

CompletedNCT03216473

Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm

A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of NEURONOX® vs. BOTOX® in Patients With Essential Blepharospasm

Status: Completed
Phase: Phase 3
Study type: Interventional
Enrollment: 140 (actual)

Sponsor: Medy-Tox · Industry
Sex: All
Age: 18 Years – 75 Years
Healthy volunteers: Accepted

Summary

This clinical study evaluates the efficacy and safety of Neuronox compared with Botox in adults with essential blepharospasm.

Detailed description

Subjects are randomly assigned into the two groups at the ratio of 1:1. The purpose of study is to confirm the non-inferiority of Neuronox to Botox in terms of the efficacy and safety in subjects with essential blepharospasm.

Conditions

Essential Blepharospasm

Interventions

Type	Name	Description
DRUG	Neuronox	Clostridium Botulinum Toxin A 100 U
DRUG	Botox	Clostridium Botulinum Toxin A 100 U

Timeline

Start date: 2016-05-25
Primary completion: 2017-03-17
Completion: 2017-07-04
First posted: 2017-07-13
Last updated: 2017-07-13

Source: ClinicalTrials.gov record NCT03216473. Inclusion in this directory is not an endorsement.